142 related articles for article (PubMed ID: 9476987)
1. Antisense oligodeoxynucleotides to the kappa1 receptor enhance delta9-THC-induced antinociceptive tolerance.
Rowen DW; Embrey JP; Moore CH; Welch SP
Pharmacol Biochem Behav; 1998 Feb; 59(2):399-404. PubMed ID: 9476987
[TBL] [Abstract][Full Text] [Related]
2. A diminution of delta9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development.
Mason DJ; Lowe J; Welch SP
Eur J Pharmacol; 1999 Sep; 381(2-3):105-11. PubMed ID: 10554877
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord.
Pugh G; Abood ME; Welch SP
Brain Res; 1995 Aug; 689(1):157-8. PubMed ID: 8528701
[TBL] [Abstract][Full Text] [Related]
4. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.
Smith PB; Welch SP; Martin BR
J Pharmacol Exp Ther; 1994 Mar; 268(3):1381-7. PubMed ID: 8138952
[TBL] [Abstract][Full Text] [Related]
5. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
6. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat.
Cox ML; Welch SP
Eur J Pharmacol; 2004 Jun; 493(1-3):65-74. PubMed ID: 15189765
[TBL] [Abstract][Full Text] [Related]
7. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.
Cichewicz DL; Martin ZL; Smith FL; Welch SP
J Pharmacol Exp Ther; 1999 May; 289(2):859-67. PubMed ID: 10215664
[TBL] [Abstract][Full Text] [Related]
8. Two distinctive antinociceptive systems in rats with pathological pain.
Mao J; Price DD; Lu J; Keniston L; Mayer DJ
Neurosci Lett; 2000 Feb; 280(1):13-6. PubMed ID: 10696800
[TBL] [Abstract][Full Text] [Related]
9. Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice.
Chopda GR; Parge V; Thakur GA; Gatley SJ; Makriyannis A; Paronis CA
J Pharmacol Exp Ther; 2016 Aug; 358(2):334-41. PubMed ID: 27231154
[TBL] [Abstract][Full Text] [Related]
10. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
[TBL] [Abstract][Full Text] [Related]
11. Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal.
Gerak LR; France CP
J Pharmacol Exp Ther; 2016 May; 357(2):357-66. PubMed ID: 26937020
[TBL] [Abstract][Full Text] [Related]
12. A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse.
Bloom AS; Dewey WL
Psychopharmacology (Berl); 1978 May; 57(3):243-8. PubMed ID: 97703
[TBL] [Abstract][Full Text] [Related]
13. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems.
Welch SP
Drug Alcohol Depend; 1997 Apr; 45(1-2):39-45. PubMed ID: 9179505
[TBL] [Abstract][Full Text] [Related]
14. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors.
Ghozland S; Matthes HW; Simonin F; Filliol D; Kieffer BL; Maldonado R
J Neurosci; 2002 Feb; 22(3):1146-54. PubMed ID: 11826143
[TBL] [Abstract][Full Text] [Related]
15. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
Houser SJ; Eads M; Embrey JP; Welch SP
Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
[TBL] [Abstract][Full Text] [Related]
16. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
17. Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells.
Di Toro R; Campana G; Sciarretta V; Murari G; Spampinato S
Life Sci; 1998; 63(14):PL197-204. PubMed ID: 9771917
[TBL] [Abstract][Full Text] [Related]
18. Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol.
McKinney DL; Cassidy MP; Collier LM; Martin BR; Wiley JL; Selley DE; Sim-Selley LJ
J Pharmacol Exp Ther; 2008 Feb; 324(2):664-73. PubMed ID: 17967938
[TBL] [Abstract][Full Text] [Related]
19. The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol.
Smith FL; Cichewicz D; Martin ZL; Welch SP
Pharmacol Biochem Behav; 1998 Jun; 60(2):559-66. PubMed ID: 9632241
[TBL] [Abstract][Full Text] [Related]
20. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.
Fan F; Compton DR; Ward S; Melvin L; Martin BR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1383-90. PubMed ID: 7996450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
